

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6001280

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
MIDCAP FINANCIAL TRUST, AS AGENT	02/28/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	APTEVO THEAPEUTICS INC.
<b>Street Address:</b>	2401 4TH AVENUE, SUITE 1050
<b>City:</b>	SEATTLE
<b>State/Country:</b>	WASHINGTON
<b>Postal Code:</b>	98121
<b>Name:</b>	APTEVO BIOTHERAPEUTICS LLC
<b>Street Address:</b>	2401 4TH AVENUE, SUITE 1500
<b>City:</b>	SEATTLE
<b>State/Country:</b>	WASHINGTON
<b>Postal Code:</b>	98121
<b>Name:</b>	APTEVO RESEARCH AND DEVELOPMENT LLC
<b>Street Address:</b>	2401 4TH AVENUE, SUITE 1050
<b>City:</b>	SEATTLE
<b>State/Country:</b>	WASHINGTON
<b>Postal Code:</b>	98121

**PROPERTY NUMBERS Total: 36**

Property Type	Number
Patent Number:	9587008
Patent Number:	8106161
Patent Number:	8197810
Patent Number:	9005612
Patent Number:	8188237
Patent Number:	7829084
Patent Number:	8147835
Patent Number:	8853366
Patent Number:	10143748
Patent Number:	8409577

PATENT

Property Type	Number
Patent Number:	9493564
Patent Number:	9101609
Patent Number:	8333966
Patent Number:	9782478
Patent Number:	7846434
Patent Number:	8383106
Application Number:	15875373
Application Number:	16028736
Application Number:	14860042
Application Number:	11493132
Application Number:	16172096
Application Number:	15617833
Application Number:	15281441
Application Number:	15040744
Application Number:	15802636
Application Number:	15699474
Application Number:	14395689
Application Number:	15126922
Application Number:	15550143
Application Number:	15761499
Application Number:	15933324
Application Number:	62648072
Application Number:	16041309
Application Number:	62667404
Application Number:	62667402
PCT Number:	US2017052808

#### CORRESPONDENCE DATA

**Fax Number:** (703)610-6200

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 7036106100

**Email:** boxip@hoganlovells.com

**Correspondent Name:** RACHEL FLEESON OF HOGAN LOVELLS US LLP

**Address Line 1:** 8350 BROAD STREET, 17TH FLOOR

**Address Line 2:** ATTN: BOX INTELLECTUAL PROPERTY

**Address Line 4:** TYSONS, VIRGINIA 22102

**ATTORNEY DOCKET NUMBER:** 36639.114

**NAME OF SUBMITTER:** RACHEL FLEESON OF HOGAN LOVELLS US LLP

<b>SIGNATURE:</b>	/rsf/
<b>DATE SIGNED:</b>	03/06/2020
<b>Total Attachments: 10</b> source=Midcap _ Aptevo _ IPSA Termination - patents#page1.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page2.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page3.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page4.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page5.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page6.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page7.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page8.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page9.tif source=Midcap _ Aptevo _ IPSA Termination - patents#page10.tif	

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This Release of Security Interest in Intellectual Property, dated as of February 28, 2020, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **APTEVO THERAPEUTICS INC.**, a Delaware corporation (“**Aptevo Therapeutics**”), **APTEVO BIOTHERAPEUTICS LLC** a Delaware limited liability company (“**Aptevo BioTherapeutics**”), and **APTEVO RESEARCH AND DEVELOPMENT LLC**, a Delaware limited liability company (“**Aptevo R&D**” and together with Aptevo Therapeutics and Aptevo BioTherapeutics, each a “**Grantor**” and collectively, the “**Grantors**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of February 7, 2019 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on February 7, 2019 at Reel/Frame No. 6555/0001 (Trademarks) and at Reel/Frame No. 048270/0813 (Patents), Grantors granted Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of Grantors’ intellectual property, including those listed on Exhibits A through D thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule A attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule B attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of each IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantor’s sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Security Interest in Intellectual Property to be duly executed and delivered by its duly authorized officer as of the date first written above.

**AGENT:**

**MIDCAP FINANCIAL TRUST**  
as Agent

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By: 

Name: Maurice Amsellem

Title: Authorized Signatory

**SCHEDULE B**

**[See attached]**

A. Patents

Method of producing biologically active vitamin K dependent proteins by recombinant methods						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.40900	US	Pending	15/875,373	19-Jan-2018		

METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.40901	US	Granted	14/475,881	03-Sep-2014	9,587,008	07-Mar-2017

STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.40902	US	Pending	16/028,736	06-July-2018		

RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH STATIC ACID CONTENT AND METHODS OF PREPARING SAME						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.40903	US	Pending	14/860,042	21-Sep-2015		

BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80011a	US	Granted	11/088,693	23-Mar-2005	8,106,161	31-Jan-2012
APVO.80011a	US	Granted	12/901,297	08-Oct-2010	8,197,810	12-Jun-2012
APVO.80011a	US	Granted	13/451,641	20-Apr-2012	9,005,612	14-Apr-2015
APVO.80011a	US	Granted	12/901,295	08-Oct-2010	8,188,237	29-May-2012

BINDING CONSTRUCTS AND METHODS FOR USE THEREOF						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80011c	US	Granted	10/627,556	26-Jul-2003	7,829,084	09-Nov-2010

BINDING CONSTRUCTS AND METHODS FOR USE THEREOF						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80011b	US	Granted	12/541,062	13-Aug-2009	8,147,835	03-Apr-2012
APVO.80011b	US	Granted	13/396,147	14-Feb-2012	8,853,366	07-Oct-2014



B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80100	US	Pending	11/493,132	25-Jul-2006		
APVO.80100	US	Granted	13/836,103	15-Mar-2013	10,143,748	04-Dec-2018
APVO.80100	US	Pending	16/172,096	26-Oct-2018		

SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80102	US	Granted	12/304,562	22-Jul-2010	8,409,577	02-Apr-2013
APVO.80102	US	Pending	15/617,833	8-June-2017		

CD86 Antagonist Multi-Target Binding Proteins						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80116	US	Granted	13/122,383	15-May-2011	9,493,564	15-Nov-2016
APVO.80116	US	Pending	15/281,441	30-Sep-2016		

TCR Complex Immunotherapeutics						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80117	US	Pending	15/040,744	10-Feb-2016		

CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80120	US	Granted	12/422,780	13-Apr-2009	9,101,609	11-Aug-2015
APVO.80120	US	Granted	12/678,857	15-Jul-2010	8,333,966	18-Dec-2012

Heterodimer Binding Proteins and Uses Thereof						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80121	US	Pending	15/802,636	03-Nov-2017		

Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80124	US	Granted	15/585,921	03-May-2017	9,782,478	10-Oct-2017
APVO.80124	US	Pending	15/699,474	8-Sep-2017		

CD3 BINDING POLYPEPTIDES								
Docket Number	Country			Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80126	US			Pending	14/395,689	20-Oct-2014		

Cell Line-Based Redirected T-Cell Cytotoxicity Assay						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80135	US	Pending	15/126,922	16-Sep-2016		

Compositions and Methods for Combination Therapy with Prostate-Specific Membrane Antigen Binding Proteins						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80137	US	Pending	15/550,143	10-Aug-2017		

CD3 Binding Polypeptides						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80138	US	Pending	15/761,499	20-Mar-2018		

CD123 Binding Proteins and Related Compositions and Methods						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80141	PCT	Pending	PCT/US2017/052808	21-Sep-2017		
APVO.80141	US	Pending	15/933,324	22-March-2018		

Oncofetal Antigen Binding Proteins and Related Compositions and Methods						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APVO.80142	US	Pending	62/648,072	26-Mar-2018		
APVO.80142	US	Pending	16/041,309	20-July-2018		

Protein Therapeutics For Cytokine Delivery						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APV/O.80144	US	Pending	62/667,404	04-May-2018		

Formulations Of Protein Therapeutics						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APV0.80145	US	Pending	62/667,402	04-May-2018		

Materials And Methods For Improved Immunoglobulins						
Docket Number	Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
APV/O.80105US1	US	Pending	12/082,497	11-Apr-2008	7,846,434	07-Dec-2010
APV/O.80105aUS2	US	Pending	12/909,769	21-Oct-2010	8,383,106	26-Feb-2013

198925624 v1